TriCor Purchasers Seek To Finalize $65M Settlement

Law360, New York (September 21, 2009, 3:01 PM EDT) -- A class of indirect purchasers has requested final approval of a proposed allocation plan for a $65.7 million settlement of a consolidated action accusing Abbott Laboratories and Fournier Industrie et Sante of blocking generic competition for the cholesterol drug TriCor.

Two-thirds of the settlement amount would be distributed among both individuals and entities in the U.S. who purchased fenofibrate products, sold by Abbott under the brand name TriCor, between April 2002 and May 2009, according to the motion filed Friday in the U.S. District Court for...
To view the full article, register now.